Robin Bhattacherjee BSc (Hons) joined Actimed Therapeutics as CEO in August 2019. Robin was previously with Actelion from 2009 and was the General Manager for the UK and Ireland Affiliate and a member of the European Management Team.
 
Robin served on the ABPI Board of Management from 2011 – 2017 as one of the elected Small Companies Group representatives, with a particular interest in medicines that come under specialised commissioning. Prior to Actelion, Robin was the General Manager for CV Therapeutics Europe (CVT) from 2004 to mid-2009, prior to the acquisition of the Company by Gilead. Responsibilities included delivering the European licencing and pre-marketing objectives for the product portfolio and the build and management of European affiliates. He also played a major role in successful European business development activities. Robin joined CVT from Sanofi-Synthélabo UK, where he was Head of Marketing and he also sat on the Irbesartan Global Strategy Team.
 
From 1986 to 2002, Robin held a variety of positions at Bayer including Marketing Manager and National Sales Manager in the UK and he was a Director in Bayer’s Global Strategic Marketing Group. During his career, Robin has been involved in several product launches both in the UK and Europe. Robin grew up in the North West of England and has an honours degree in Biological Sciences gained at University of London.

Fabio Dorigotti  MD brings over 25 years of pharmaceutical industry experience spanning the full breadth of the clinical development process. Prior to joining Actimed, Dr Dorigotti was CMO of Swiss biopharmaceutical company Quercis Pharma. During his career, Dr Dorigotti has held inhouse roles of Head of Global Medical Affairs for CSL Vifor and Medical Affairs Director at AstraZeneca, and as Chief Strategy Officer and President of Global Clinical for Worldwide Clinical Trials, a full-service global contract research organization (CRO). He has a strong track record of successful clinical development and product marketing approvals, alongside a deep understanding of FDA, EMA and other regulatory agencies.  

Elaine Morten, PhD began working with Actimed in 2017 as a consultant before joining the Company in 2022. Elaine brings over 25 years of global drug development experience to Actimed predominantly obtained in small to mid-size organisations.  Elaine has a track record of taking products through development to marketing authorisation and beyond and has diverse therapeutic and territorial experience.  Prior to joining Actimed, Elaine was an independent consultant to the Pharmaceutical Industry and before this, she was Vice President of Regulatory Affairs and Head of Pharmacovigilance at The Medicines Company. Elaine has also worked for British Biotech as Head of Regulatory Affairs and Shire Pharmaceuticals as Regulatory Affairs Manager. 

Louise Bosworth is the Head of Clinical Operations and Quality for Actimed, responsible for leading the Clinical Operations Strategy and delivering the Clinical Development Programme. With over 25 years of Clinical Development and Quality experience in the pharmaceutical industry, Louise joined Actimed in September 2021. Louise has held senior positions at large pharma companies including Eli Lilly & Company and Amgen as well as smaller biopharma companies, GW Pharma and Orphalan. Louise has also worked for the leading Clinical Research Organisation IQVIA. Louise’s extensive quality experience includes establishing Quality Management Systems, leading both local and international inspection readiness programs as well as regulatory inspections. Her broad therapeutic and management responsibilities incorporate Clinical and Quality expertise across the industry including fields of oncology and rare diseases products. 

Hugh Jackson is a finance professional with more than 30 years’ experience. He specializes in providing SMEs with business growth and strategic planning advice together with management reporting and compliance assurance. Over this period, working with owner-managers, business angels and venture capitalists, Hugh has assisted in completing more than 20 successful exit transactions, together with several fundraising transactions, including a Nasdaq flotation and several SEIS / EIS fundraises.

Hugh studied at Exeter University and qualified as a chartered accountant with Price Waterhouse in 1988. He established his own accountancy practice, Jacksons, in 1990.